AbbVie Inc.
AbbVie Reports 2023 Financial Results and Announces Acquisitions
Summary
AbbVie Inc. reported financial results for the fourth quarter and full year ended December 31, 2023, showing a decrease in GAAP diluted EPS and net revenues. The company experienced significant revenue declines primarily due to biosimilar competition affecting Humira sales. Despite these challenges, AbbVie announced positive results from its product pipeline and entered into definitive agreements to acquire ImmunoGen and Cerevel Therapeutics, which will strengthen its oncology and neuroscience portfolios. The company also provided guidance for 2024, anticipating modest operational revenue growth and a return to robust growth in 2025.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement